Kutane Sarkoidose

ZUSAMMENFASSUNG

Die Sarkoidose ist eine Multisystemerkrankung, deren Ursache bislang ungeklärt ist. Pathognomonisch sind nicht verkäsende Granulome, die alle Gewebe oder Organsysteme betreffen können. Aufgrund der guten klinischen Sichtbarkeit der kutanen Sarkoidose ist diese oft der erste Hinweis für das Vorliegen einer systemischen Sarkoidose. Die Dermatologie spielt somit eine wichtige Rolle bei der Früherkennung dieser multisystemischen Erkrankung. Eine reine Hautmanifestation ohne systemische Beteiligung ist möglich. Die häufigsten Vertreter hierfür sind die makulopapulöse und die noduläre Sarkoidose. Zum anderen gibt es unspezifische Hautmanifestationen, wie zum Beispiel das Erythema nodosum, welches im Rahmen einer systemischen Sarkoidose auftreten kann. Die Diagnose wird mittels Gewebebiopsie gestellt. Die Biomarker CRP, sIl-2R und Neopterin können bei Hautmanifestation Hinweis für eine systemische Beteiligung sein. Die Therapie richtet sich nach Schwere der Hautmanifestation und systemischer Beteiligung. Zur Behandlung der kutanen Sarkoidose zugelassen sind topische, intraläsionale oder systemische Glukokortikosteroide. Bei therapierefraktären Verläufen können off-label immunmodulierende oder immunsuppressive Medikamente eingesetzt werden.

Schlüsselwörter

Kutane Sarkoidose - Erythema nodosum - Lupus pernio - Darier-Roussy-Sarkoidose - makulopapulöse Sarkoidose

Publication History

Article published online:
08 October 2024

• Literatur

• 1 Tchernev G. Cutaneous Sarcoidosis: The ‘Great Imitator’. Am J Clin Dermatol 2006; 7: 375-382 DOI: 10.2165/00128071-200607060-00006.
• 2 Rybicki BA, Major M, Popovich J. et al Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 1997; 145: 234-241 DOI: 10.1093/oxfordjournals.aje.a009096.
• 3 Baughman RP, Field S, Costabel U. et al Sarcoidosis in America. Analysis Based on Health Care Use. Ann Am Thorac Soc 2016; 13: 1244-1252 DOI: 10.1513/AnnalsATS.201511-760OC.
• 4 Park JE, Kim YS, Kang MJ. et al Prevalence, incidence, and mortality of sarcoidosis in Korea, 2003–2015: A nationwide population-based study. Respiratory Medicine 2018; 144: S28-S34 DOI: 10.1016/j.rmed.2018.03.028.
• 5 Wu C-H, Chung P-I, Wu C-Y. et al Comorbid autoimmune diseases in patients with sarcoidosis: A nationwide case-control study in Taiwan. J Dermatol 2017; 44: 423-430 DOI: 10.1111/1346-8138.13654.
• 6 Lodha S, Sanchez M, Prystowsky S. arcoidosis of the Skin: A Review for the Pulmonologist. Chest 2009; 136: 583-596 DOI: 10.1378/chest.08-1527.
• 7 Hanno R, Needelman A, Eiferman RA, Callen JPR H A N Ra E. et al Cutaneous sarcoidal granulomas and the development of systemic sarcoidosis. Archives of dermatology 1981; 117
• 8 English JC, 3^rd Patel PJ, Greer KE. Sarcoidosis. Journal of the American Academy of Dermatology 2001; (44) DOI: 10.1067/mjd.2001.114596.
• 9 Samtsov AV. Cutaneous sarcoidosis. Int J Dermatol 1992; 31: 385-391 DOI: 10.1111/j.1365-4362.1992.tb02664.x.
• 10 Yanardağ H, Pamuk ON, Karayel T. Cutaneous involvement in sarcoidosis: analysis of the features in 170 patients. Respir Med 2003; 97: 978-982 DOI: 10.1016/s0954-6111(03)00127-6.
• 11 Ungprasert P, Wetter DA, Crowson CS. et al Epidemiology of cutaneous sarcoidosis, 1976–2013: a population-based study from Olmsted County, Minnesota. Journal of the European Academy of Dermatology and Venereology 2016; 30: 1799-1804 DOI: 10.1111/jdv.13760.
• 12 Mañá J, Marcoval J, Graells J. et al Cutaneous involvement in sarcoidosis. Relationship to systemic disease. Arch Dermatol 1997; 133: 882-888 DOI: 10.1001/archderm.1997.03890430098013.
• 13 James DG. Dermatological aspects of sarcoidosis. Q J Med 1959; 28: 108-124
• 14 Lundkvist A, Kullberg S, Arkema EV. et al Differences in disease presentation between men and women with sarcoidosis: A cohort study. Respiratory Medicine 2022; 191: 106688 DOI: 10.1016/j.rmed.2021.106688.
• 15 Ungprasert P, Crowson CS, Matteson EL. Influence of Gender on Epidemiology and Clinical Manifestations of Sarcoidosis: A Population-Based Retrospective Cohort Study 1976–2013. Lung 2017; 195: 87-91 DOI: 10.1007/s00408-016-9952-6.
• 16 Grunewald J, Eklund A. Sex-specific manifestations of Löfgren’s syndrome. Am J Respir Crit Care Med 2007; 175: 40-44 DOI: 10.1164/rccm.200608-1197OC.
• 17 Thi Hong Nguyen C, Kambe N, Kishimoto I. et al Serum soluble interleukin-2 receptor level is more sensitive than angiotensin-converting enzyme or lysozyme for diagnosis of sarcoidosis and may be a marker of multiple organ involvement. The Journal of Dermatology 2017; 44: 789-797 DOI: 10.1111/1346-8138.13792.
• 18 Boch K, Langan EA, Zillikens D. et al Evaluation of clinical and laboratory characteristics of patients with cutaneous sarcoidosis: A single-center retrospective cohort study. Front Med (Lausanne) 2022; 9: 980507 DOI: 10.3389/fmed.2022.980507.
• 19 Haimovic A, Sanchez M, Judson MA. et al Sarcoidosis: A comprehensive review and update for the dermatologist: Part I. Cutaneous disease. Journal of the American Academy of Dermatology 2012; 66: 699.e1-699.e18 DOI: 10.1016/j.jaad.2011.11.965.
• 20 Sanchez M, Haimovic A, Prystowsky S. Sarcoidosis. Dermatologic Clinics 2015; 33: 389-416 DOI: 10.1016/j.det.2015.03.006.
• 21 Caplan A, Rosenbach M, Imadojemu S. Cutaneous Sarcoidosis. Semin Respir Crit Care Med 2020; 41: 689-699 DOI: 10.1055/s-0040-1713130.
• 22 Ball NJ, Kho GT, Martinka M. The histologic spectrum of cutaneous sarcoidosis: a study of twenty-eight cases. Journal of Cutaneous Pathology 2004; 31: 160-168 DOI: 10.1111/j.0303-6987.2004.00157.x.
• 23 Ezeh N, Caplan A, Rosenbach M. et al Cutaneous Sarcoidosis. Dermatologic Clinics 2023; 41: 455-470 DOI: 10.1016/j.det.2023.02.012.
• 24 Elgart ML. Cutaneous sarcoidosis: Definitions and types of lesions. Clinics in Dermatology 1986; 4: 35-45 DOI: 10.1016/0738-081X(86)90032-5.
• 25 Fernandez-Faith E, McDonnell J. Cutaneous sarcoidosis: differential diagnosis. Clinics in Dermatology 2007; 25: 276-287 DOI: 10.1016/j.clindermatol.2007.03.004.
• 26 Okamoto H, Horio T, Izumi T. Micropapular sarcoidosis simulating lichen nitidus. Dermatologica 1985; 170: 253-255 DOI: 10.1159/000249543.
• 27 Marcoval J, Mañá J, Rubio M. Specific cutaneous lesions in patients with systemic sarcoidosis: relationship to severity and chronicity of disease. Clinical and Experimental Dermatology 2011; 36: 739-744 DOI: 10.1111/j.1365-2230.2011.04128.x.
• 28 Marchell RM, Judson MA. Cutaneous sarcoidosis. Semin Respir Crit Care Med 2010; 31: 442-451 DOI: 10.1055/s-0030-1262212.
• 29 Katta R. Cutaneous Sarcoidosis: A Dermatologic Masquerader. afp 2002; 65: 1581-1585
• 30 Veien NK, Stahl D, Brodthagen H. Cutaneous sarcoidosis in Caucasians. J Am Acad Dermatol 1987; 16: 534-540 DOI: 10.1016/s0190-9622(87)70070-x.
• 31 James DG. Lupus Pernio. Lupus 1992; 1 (03) 129-131 DOI: 10.1177/096120339200100302.
• 32 Spiteri MA, Matthey F, Gordon T. et al Lupus pernio: a clinico-radiological study of thirty-five cases. British Journal of Dermatology 1985; 112: 315-322 DOI: 10.1111/j.1365-2133.1985.tb04859.x.
• 33 Neville E, Mills RG, Jash DK. et al Sarcoidosis of the upper respiratory tract and its association with lupus pernio. Thorax 1976; 31: 660-664
• 34 Epstein WL. Cutaneous Sarcoidosis. Semin Respir Crit Care Med 2002; 23: 571-578 DOI: 10.1055/s-2002-36525.
• 35 Cecchi R, Giomi A. Scar sarcoidosis following herpes zoster. J Eur Acad Dermatol Venereol 1999; 12: 280-282 DOI: 10.1111/j.1468-3083.1999.tb01052.x.
• 36 Kormeili T, Neel V, Moy RL. Cutaneous sarcoidosis at sites of previous laser surgery. Cutis 2004; 73: 53-55
• 37 Usmani N, Akhtar S, Long E. et al A case of sarcoidosis occurring within an extensive burns scar. Journal of Plastic, Reconstructive & Aesthetic Surgery 2007; 60: 1256-1259 DOI: 10.1016/j.bjps.2006.03.056.
• 38 Zhao S, Wang Q, Cheng B. et al Rare scar sarcoidosis: A case report. Exp Ther Med. 2017; 13: 1535-1537 DOI: 10.3892/etm.2017.4123.
• 39 Antonovich DD, Callen JP. Development of sarcoidosis in cosmetic tattoos. Arch Dermatol 2005; 141: 869-872 DOI: 10.1001/archderm.141.7.869.
• 40 Scarfi F, Arunachalam M, Galeone M. et al Nodular Lesions on Post-surgical Scars: A Quiz. Acta Dermato-Venereologica 2013; 93: 251-254 DOI: 10.2340/00015555-1407.
• 41 Chudomirova K, Velichkova L, Anavi B. et al Recurrent sarcoidosis in skin scars accompanying systemic sarcoidosis. Journal of the European Academy of Dermatology and Venereology 2003; 17: 360-361 DOI: 10.1046/j.1468-3083.2003.00792_9.x.
• 42 Mathis AK, Johnson BA. An Impressive Finding of Sarcoid-Like Reaction to Tattooing. Cureus 15: e35401 DOI: 10.7759/cureus.35401.
• 43 Leverenz DL, Henderson C, Shah A. Atypical Cutaneous Presentations of Sarcoidosis: Two Case Reports and Review of the Literature. Curr Allergy Asthma Rep 2018; 18: 40 DOI: 10.1007/s11882-018-0794-6.
• 44 Simunovic C, Shinohara MM. Complications of decorative tattoos: recognition and management. Am J Clin Dermatol 2014; 15: 525-536 DOI: 10.1007/s40257-014-0100-x.
• 45 Islam PS, Chang C, Selmi C. et al Medical Complications of Tattoos: A Comprehensive Review. Clinic Rev Allerg Immunol 2016; 50: 273-286 DOI: 10.1007/s12016-016-8532-0.
• 46 Youn P, Francis RJ, Preston H. et al Subcutaneous sarcoidosis (Darier–Roussy sarcoidosis) with extensive disease on positron emission tomography: A case report and review of the literature. Respirology Case Reports 2022; 10: e0949 DOI: 10.1002/rcr2.949.
• 47 Wanat KA, Rosenbach M. A Practical Approach to Cutaneous Sarcoidosis. Am J Clin Dermatol 2014; 15: 283-297 DOI: 10.1007/s40257-014-0079-3.
• 48 Pérez-Garza DM, Chavez-Alvarez S, Ocampo-Candiani J, Gomez-Flores M. Erythema Nodosum: A Practical Approach and Diagnostic Algorithm. Am J Clin Dermatol 2021; 22 (03) 367-378 DOI: 10.1007/s40257-021-00592-w.
• 49 Ahmed I, Harshad SR. Subcutaneous sarcoidosis: Is it a specific subset of cutaneous sarcoidosis frequently associated with systemic disease?. Journal of the American Academy of Dermatology 2006; 54: 55-60 DOI: 10.1016/j.jaad.2005.10.001.
• 50 Doherty CB, Rosen T. Evidence-based therapy for cutaneous sarcoidosis. Drugs 2008; 68: 1361-1383 DOI: 10.2165/00003495-200868100-00003.
• 51 Russo G, Millikan LE. Cutaneous sarcoidosis: diagnosis and treatment. Compr Ther 1994; 20: 418-421
• 52 Green CM. Topical tacrolimus for the treatment of cutaneous sarcoidosis. Clin Exp Dermatol 2007; 32: 457-458 DOI: 10.1111/j.1365-2230.2007.02397.x.
• 53 Badgwell C, Rosen T. Cutaneous sarcoidosis therapy updated. J Am Acad Dermatol 2007; 56: 69-83 DOI: 10.1016/j.jaad.2006.06.019.
• 54 Cohen E, Lheure C, Ingen-Housz-Oro S. et al Which first-line treatment for cutaneous sarcoidosis? A retrospective study of 120 patients. Eur J Dermatol 2023; 33: 680-685 DOI: 10.1684/ejd.2023.4584.
• 55 Toriola SL, Satnarine T, Zohara Z. et al Recent Clinical Studies on the Effects of Tumor Necrosis Factor-Alpha (TNF-α) and Janus Kinase/Signal Transducers and Activators of Transcription (JAK/STAT) Antibody Therapies in Refractory Cutaneous Sarcoidosis: A Systematic Review. Cureus 2023; 15: e44901 DOI: 10.7759/cureus.44901.
• 56 Heidelberger V, Ingen-Housz-Oro S, Marquet A. et al Efficacy and Tolerance of Anti-Tumor Necrosis Factor α Agents in Cutaneous Sarcoidosis: A French Study of 46 Cases. JAMA Dermatol 2017; 153: 681-685 DOI: 10.1001/jamadermatol.2017.1162.
• 57 Sakkat A, Cox G, Khalidi N. et al Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis. Respir Res 2022; 23: 54 DOI: 10.1186/s12931-022-01971-5.
• 58 Damsky W, Kole L, Tomayko MM. Development of bullous pemphigoid during nivolumab therapy. JAAD Case Rep 2016; 2: 442-444 DOI: 10.1016/j.jdcr.2016.05.009.